Sonoma Pharmaceuticals, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Discontinued Operations: Sale of Assets to Infinity Labs SD, Inc. (Details Narrative)

Discontinued Operations: Sale of Assets to Infinity Labs SD, Inc. (Details Narrative) - USD ($)	3 Months Ended		9 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2021	Dec. 31, 2020
Discontinued Operations and Disposal Groups [Abstract]
Income (loss) from discontinued operations, net of tax	$ 0	$ (24,000)	$ 0	$ 893,000
Income (loss) from discontinued operations, net of tax	$ 0	$ 24,000	$ 0	(893,000)
Gain on disposal of discontinued operations				$ 795,000

- Definition

Amount before tax of income (loss) from a discontinued operation. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.

+ References + Details